Jubilant Pharmova posts 14% FY26 revenue growth to Rs. 8,280 crore amid margin pressure
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
BMS is moving beyond conversational AI into what it describes as “agentic” systems
The company reported free cash flow of Rs. 2,590 Mn for FY26
Union health ministry secretary Punya Salila Srivastava lauds HLL’s six decades of contribution to public healthcare and social development
Deployment aims to improve serialization efficiency by 45% and enhance regulatory compliance across global export markets
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
Subscribe To Our Newsletter & Stay Updated